Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
Oncotelic Therapeutics (OTLC) announced that CEO Vuong Trieu will present its Deciparticle nanomedicine platform at BIO International Convention 2026 in San Diego. The presentation highlights progress on Sapu006 (IV docetaxel) entering Phase 1b and Sapu003 (IV everolimus) in global Phase 1b trials, alongside the integration of AI via the PDAOAI platform.
Key figures
- Particle size
- sub-20 nanometer
- Issued patents
- 75
- Gmp bio interest
- 45%
- Patent applications
- 500+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.